SLN

Silence Therapeutics Plc ADR

19.78

Nov 03 • 3:59 PM ET +0.02 (0.10%)

19.60

Aftermarket • 7:30 PM ET -0.18 (-0.91%)

Healthcare Biotechnology United Kingdom Small NASD

Peers: ARWR ALNY IONS SCTX PTGX WVE ABUS NAMS ARCT AMGN

| Held by: IBB ARB HXA GWX APIE EVNT IBBQ BIB

Scroll to Statements

Index	-
Market Cap	1.23B
Enterprise Value	1.16B
Income	-59.80M
Sales	0.61M
Book/sh	0.81
Cash/sh	1.16
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	88
IPO	Sep 08, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	2015.29
P/B	24.29
P/C	17.06
P/FCF	-
EV/EBITDA	-
EV/Sales	1897.36
Quick Ratio	7.42
Current Ratio	7.42
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.27
EPS next Y	-0.55
EPS next Q	-0.11
EPS this Y	42.06%
EPS next Y	-51.08%
EPS next 5Y	-1.68%
EPS past 3/5Y	-6.68% -4.20%
Sales past 3/5Y	-70.38% -39.70%
EPS Y/Y TTM	24.26%
Sales Y/Y TTM	-
EPS Q/Q	55.62%
Sales Q/Q	-100.00%
Earnings	Aug 10 BMO
EPS/Sales Surpr.	35.11% -91.44%

Insider Own	16.46%
Insider Trans	0.00%
Inst Own	26.83%
Inst Trans	13.83%
ROA	-44.03%
ROE	-90.18%
ROIC	-155.41%
Gross Margin	15.82%
Oper. Margin	-10478.17%
Profit Margin	-9751.68%
SMA20	27.09%
SMA50	43.96%
SMA200	114.99%
Trades

Shs Outstand	62.15M
Shs Float	51.92M
Short Float	5.64%
Short Ratio	1.07
Short Interest	2.93M
52W High	19.86 -0.43%
52W Low	4.19 372.08%
Volatility	0.31% 3.32%
ATR (14)	0.67
RSI (14)	78.99
Beta	1.35
Rel Volume	0.13
Avg Volume	2.74M
Volume	352,415

Perf Week	0.00%
Perf Month	95.07%
Perf Quarter	75.98%
Perf Half Y	177.03%
Perf YTD	225.33%
Perf Year	199.24%
Perf 3Y	115.00%
Perf 5Y	-8.13%
Perf 10Y	-
Recom	2.60
Target Price	20.00
Prev Close	19.76
Price	19.78
Change %	0.10%

Consensus

Hold

Avg. Price Target

$20.00

Implied Upside

+1.1%

Analysts4incl. previous ratings

Rating Distribution3 Buy · 0 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jun 24, 2026	Initiated	CCantor Fitzgerald	Overweight
Feb 11, 2025	Initiated	GGoldman	Sell	$6	-69.7%
Dec 02, 2024	Reiterated	BBMO Capital Markets	Outperform
Sep 03, 2024	Initiated	JJefferies	Buy	$40	+102.2%
Jan 31, 2024	Initiated	BBMO Capital Markets	Outperform	$67	+238.7%

Oct-20-26 12:21PM	Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders? (PR Newswire)
08:59AM	A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday (PR Newswire)
Oct-19-26 11:23AM	Silence Therapeutics Agrees to $1.3 Billion Merck KGaA Acquisition at 130% Premium (InvestorsHub) +125.58%
11:20AM	Silence Therapeutics jumps 59% on Merck takeover (Proactive)
10:19AM	Why Merck KGaA Is Paying a 130% Premium For This Gene-Silencing Tech (Barrons.com)
09:56AM	Loading…
09:56AM	Silence Therapeutics stock soars 125% on Merck acquisition (Investing.com)
08:00AM	Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany (Business Wire)
Sep-02-26 08:00AM	Silence Therapeutics to Participate in Three September Investor Conferences (Business Wire)
Aug-14-26 04:55PM	Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional ADSs (Business Wire)
Aug-10-26 07:30AM	Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile (Business Wire) +29.12%
07:15AM	Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results (Business Wire)
06:13AM	Silence Therapeutics shares surge ahead of divesiran Phase 2 results call (InvestorsHub)
Aug-09-26 05:00PM	Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera (Business Wire)
Jun-11-26 07:30AM	Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera (Business Wire) +11.33%
May-27-26 08:00AM	Silence Therapeutics to Participate in Jefferies Global Healthcare Conference (Business Wire)
08:00AM	Loading…
May-12-26 08:00AM	Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference (Business Wire) -5.30%
Mar-05-26 09:55AM	Wall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High? (Zacks)
07:30AM	Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Dec-15-25 08:13AM	Silence Therapeutics Announces Leadership Changes (Business Wire)
Nov-12-25 08:00AM	Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference (Business Wire)
Nov-06-25 07:30AM	Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights (Business Wire)
Oct-23-25 07:30AM	Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV) (Business Wire)
Sep-02-25 08:00AM	Silence Therapeutics to Participate in September Investor Conferences (Business Wire)
Aug-07-25 07:30AM	Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights (Business Wire)
Jun-23-25 09:09AM	Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus (Zacks)
Jun-12-25 04:01PM	Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera (Business Wire) +6.58%
Jun-06-25 09:55AM	Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet (Zacks)
May-21-25 09:55AM	Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade (Zacks)
May-08-25 08:00AM	Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights (Business Wire)
May-06-25 07:45AM	Silence Therapeutics Welcomes Tim McInerney to Board of Directors (Business Wire)
09:24PM	Loading…
Apr-23-25 09:24PM	Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying (Insider Monkey) +8.85% +5.72%
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha) -6.78%
Mar-05-25 08:00AM	Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference (Business Wire) +5.58%
Feb-27-25 07:30AM	Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update (Business Wire)
Feb-13-25 08:00AM	Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025 (Business Wire) +9.49%
Dec-09-24 07:30AM	Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting (Business Wire) -6.22%
Nov-26-24 08:00AM	Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-18-24 02:30PM	Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting (Business Wire) -13.23%
Nov-14-24 08:00AM	Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (Business Wire) -8.27%
Nov-13-24 08:00AM	Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference (Business Wire) -5.98%
Aug-27-24 08:00AM	Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences (Business Wire)
Aug-15-24 07:30AM	Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
Jul-12-24 10:09AM	Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last? (Zacks)
Jun-27-24 07:30AM	Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients (Business Wire)
Jun-24-24 08:30AM	Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration (Business Wire)
Jun-20-24 07:30AM	Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a) (Business Wire)
May-30-24 08:30AM	Silence Therapeutics to Present at Jefferies Global Healthcare Conference (Business Wire)
May-16-24 09:53PM	SLN Stock Earnings: Silence Therapeutics Reported Results for Q1 2024 (InvestorPlace)
08:30AM	Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress (Business Wire)
Apr-30-24 08:30AM	Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference (Business Wire)
Apr-29-24 08:30AM	Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors (Business Wire)
Apr-12-24 08:21AM	Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains? (Zacks)
Apr-08-24 11:48AM	Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a) (Business Wire)
Mar-13-24 07:05AM	Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights (Business Wire)
07:00AM	Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a) (Business Wire)
Feb-28-24 08:29AM	Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock? (Zacks)
08:00AM	Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024 (Business Wire)
Feb-23-24 08:00AM	Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial (Business Wire)
Feb-05-24 08:00AM	Silence Therapeutics Announces Oversubscribed $120 Million Private Placement (Business Wire)
Feb-01-24 08:19AM	Strength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength? (Zacks)
Jan-31-24 07:00AM	Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (Business Wire) +15.44%
Jan-17-24 08:00AM	INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors (GlobeNewswire)
Jan-11-24 12:00PM	All You Need to Know About Silence Therapeutics PLC Sponsored ADR (SLN) Rating Upgrade to Strong Buy (Zacks)
Dec-01-23 07:00AM	Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments (Business Wire) +5.28%
Nov-14-23 07:00AM	Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-08-23 07:00AM	Silence Therapeutics to Present at Jefferies London Healthcare Conference (Business Wire)
Nov-01-23 07:00AM	Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease (Business Wire) +29.25%
Sep-26-23 07:00AM	Silence Therapeutics to Participate in Fireside Chat at Chardans 7th Annual Genetic Medicines Conference (Business Wire)
Sep-06-23 07:00AM	Silence Therapeutics to Participate in September Investor Conferences (Business Wire) -5.70%
Aug-16-23 07:00AM	Silence Therapeutics Reports Second Quarter 2023 Results (Business Wire) +6.21%
Jul-11-23 07:00AM	Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration (Business Wire)
May-31-23 07:00AM	Silence Therapeutics to Present at the Jefferies Healthcare Conference (Business Wire) -8.61%
May-16-23 04:00PM	Silence Therapeutics Reports First Quarter 2023 Results (Business Wire) -8.56%
May-04-23 07:00AM	Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration (Business Wire)
May-01-23 07:00AM	Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events (Business Wire)
Apr-25-23 07:00AM	Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference (Business Wire)
Apr-04-23 07:00AM	Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera (Business Wire)
Mar-29-23 07:00AM	Silence Therapeutics to Present at Guggenheims Genomic Medicines and Rare Disease Days (Business Wire) -22.94%
Mar-28-23 07:05AM	Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development (Business Wire)

Show Previous News

Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.

BSc (Hons)Mr. Iain Gladstone Ross B.Sc.

Executive VPMs. Rhonda L. Hellums

Executive VP and Chief Research & Development OfficerDr. Steven J. Romano M.D.

Chief Scientific OfficerDr. Marie Wikstrom Lindholm Ph.D.

SVP & General CounselMr. Jaimin B. Shah

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SLN

Silence Therapeutics Plc ADR

Upgrade your Finviz experience